These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 32037675)

  • 1. Cost-effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United Kingdom.
    Bennett H; Tank A; Evans M; Bergenheim K; McEwan P
    Diabetes Obes Metab; 2020 Jul; 22(7):1047-1055. PubMed ID: 32037675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.
    Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
    BMC Health Serv Res; 2015 Nov; 15():496. PubMed ID: 26541516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.
    Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
    Diabet Med; 2015 Jul; 32(7):890-8. PubMed ID: 25817050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.
    Tzanetakos C; Tentolouris N; Kourlaba G; Maniadakis N
    Clin Drug Investig; 2016 Aug; 36(8):649-59. PubMed ID: 27221806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands.
    van Haalen HG; Pompen M; Bergenheim K; McEwan P; Townsend R; Roudaut M
    Clin Drug Investig; 2014 Feb; 34(2):135-46. PubMed ID: 24243529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes.
    Abushanab D; Chbib S; Kaddoura R; Al Hail M; Abdul Rouf PV; El Kassem W; Shah J; Ravindran Nair RK; Al-Badriyeh D
    J Med Econ; 2024; 27(1):404-417. PubMed ID: 38390641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease.
    Tisdale RL; Cusick MM; Aluri KZ; Handley TJ; Joyner AKC; Salomon JA; Chertow GM; Goldhaber-Fiebert JD; Owens DK
    J Gen Intern Med; 2022 Oct; 37(13):3380-3387. PubMed ID: 35137296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus.
    Shao H; Zhai S; Zou D; Mir MU; Zawadzki NK; Shi Q; Liu S; Shi L
    Curr Med Res Opin; 2017 Feb; 33(2):359-369. PubMed ID: 27817216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes.
    Cai X; Shi L; Yang W; Gu S; Chen Y; Nie L; Ji L
    J Med Econ; 2019 Apr; 22(4):336-343. PubMed ID: 30663458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia.
    Cohen N; Minshall ME; Sharon-Nash L; Zakrzewska K; Valentine WJ; Palmer AJ
    Pharmacoeconomics; 2007; 25(10):881-97. PubMed ID: 17887808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of insulin pumps compared with multiple daily injections both provided with structured education for adults with type 1 diabetes: a health economic analysis of the Relative Effectiveness of Pumps over Structured Education (REPOSE) randomised controlled trial.
    Pollard DJ; Brennan A; Dixon S; Waugh N; Elliott J; Heller S; Lee E; Campbell M; Basarir H; White D;
    BMJ Open; 2018 Apr; 8(4):e016766. PubMed ID: 29627802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries.
    Sabale U; Ekman M; Granström O; Bergenheim K; McEwan P
    Prim Care Diabetes; 2015 Feb; 9(1):39-47. PubMed ID: 24840612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece.
    Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsimihodimos V; Diogo V; Karpouzos G; Papageorgiou G; Kourlaba G
    Clin Drug Investig; 2021 Apr; 41(4):371-380. PubMed ID: 33687695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF.
    McEwan P; Darlington O; McMurray JJV; Jhund PS; Docherty KF; Böhm M; Petrie MC; Bergenheim K; Qin L
    Eur J Heart Fail; 2020 Nov; 22(11):2147-2156. PubMed ID: 32749733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Dapagliflozin vs Empagliflozin for Treating Heart Failure With Reduced Ejection Fraction in the United States.
    Nechi RN; Rane A; Karaye RM; Ndikumukiza C; Alsahali S; Jatau AI; Zoni CR; Alanzi A; Karaye IM; Yunusa I
    Clin Ther; 2023 Jul; 45(7):627-632. PubMed ID: 37270374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.
    Tunis SL; Minshall ME; Conner C; McCormick JI; Kapor J; Yale JF; Groleau D
    Curr Med Res Opin; 2009 May; 25(5):1273-84. PubMed ID: 19366302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands.
    Van der Linden N; Van Olst S; Nekeman S; Uyl-de Groot CA
    Diabet Med; 2021 Apr; 38(4):e14371. PubMed ID: 32745279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China.
    Hou X; Wan X; Wu B
    Front Pharmacol; 2019; 10():480. PubMed ID: 31143117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
    Reifsnider OS; Kansal AR; Gandhi PK; Cragin L; Brand SB; Pfarr E; Fahrbach K; Ustyugova A
    BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study.
    Escobar C; Morales C; Capel M; Simón S; Pérez-Alcántara F; Pomares E
    BMC Health Serv Res; 2022 Feb; 22(1):217. PubMed ID: 35177053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.